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Aim To evaluate the dose-dependent immunogenic prop-
erties of poly(lactide-co-glycolide) (PLGA) particles coated 
with cellobiose as antigen carriers for oral immunization.
Methods Two types of PLGA-cellobiose particles (PLGA-
cellobiose-1, ~ 0.8 μm and PLGA-cellobiose-2, ~ 1.2 μm) 
containing non-toxic recombinant subunit B (SbB) of diph-
theria toxin fused with enhanced green fluorescent pro-
tein were characterized in vitro for their size, shape, antigen 
loading, and ability to induce phagocytosis. Different dos-
es of antigen, immobilized on the particles (2.5 μg, 25 μg, 
250 μg, and 2500 μg per 1 kg of body weight), were admin-
istered per os 3 times with intervals of 2 weeks to BALB/c 
female mice. The antigen-specific IgG and IgA antibodies 
were estimated in serum by ELISA.
Results After the first immunization, increase in concen-
tration of blood antitoxic antibodies was detected. Anti-
gen dose 250 μg/kg was the most immunogenic for IgG 
antibodies induction for both types of PLGA-cellobiose 
particles. Antigen doses 25 μg/kg and 2.5 μg/kg were the 
most immunogenic for IgA antibodies induction by PL-
GA-cellobiose 1 and 2 particles, respectively. The second 
and the third treatment had no significant effect on the 
immune response or even reduced it, which could be ex-
plained by immune tolerance induction by the antigens 
delivered per os.
Conclusion Our results suggest that the correct dose of 
PLGA-cellobiose particles loaded with antigen could sig-
nificantly increase the humoral immune response against 
the introduced antigen already after the first immuniza-
tion. Thus, PLGA particles can be considered as a potent 
component of oral vaccines.
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Respiratory diphtheria is a very severe disease caused by 
toxigenic strains of Corynebacterium diphtheria (1). Until 
the reemergence of diphtheria epidemic in the former So-
viet Union in the 1990s, it was considered a well-controlled 
vaccine-preventable disease. Nowadays, despite the effec-
tive childhood immunization program, the majority of the 
adult population in Europe have no immune protection 
against this infection (2,3). Therefore, a new effective vac-
cination strategy against diphtheria is desirable.
Diphtheria toxin (DT) is the main pathogenic factor of C. 
diphtheria (4). This protein consists of two fragments: A (ac-
tive) and B (binding), which are responsive for toxic effect 
and cell targeting, respectively. DT can kill mucosal cells at 
the sites of bacterial colonization and cause systemic re-
action in sensitive organisms after penetration into the 
blood. Specific antibodies can block specific binding of 
DT to cell receptor and protect the cell and the body from 
DT toxin action. Therefore, antitoxic antibodies (antitoxins) 
play the most important role in the immunity against diph-
theria. Only antibodies against B-subunit of the toxin have 
protective properties, because these antibodies can inhibit 
the toxin binding to the DT receptor.
All current diphtheria vaccines are delivered by parenteral 
route. In vaccinated persons, they can induce high levels 
of serum antitoxin, mainly of IgG class, which can prevent 
systemic spread of the toxin in the case of infection. On 
the other hand, IgA antibodies play a more important role 
than IgG antibodies in the protection of mucosal surfaces 
of the body from mucosal-associated pathogens, like C. 
diphtheriae (5).
Mucosae have their own local immune system known as 
MALT (mucosa-associated lymphoid tissue), which is able 
to develop an immune response or tolerance for antigens 
passing through the mucosal epithelium. Mucosal epi-
thelium contains a specialized cell type, known as M-cells 
(microfold cells). They can transport different particles like 
microorganisms and viruses from the mucosal surface to 
immune cells across the epithelial barrier and thus stimu-
late mucosal immunity (6). Such function of M-cells could 
be used in experimental procedures for the delivery of dif-
ferent antigens from mucosa to the immune system. The 
antigens could be delivered there by oral, nasal, vaginal, or 
other types of non-invasive vaccination (7).
Oral administration of antigens is considered the most 
patient-friendly way of immunization (8). However, the 
efficacy of oral administration of free antigens is lim-
ited by their degradation in the gastrointestinal tract and 
poor adsorption by M-cells. The development of new vac-
cines against diphtheria depends on the identification of 
antigens and new routes of immunization (9). It is expect-
ed that poly(lactide-co-glycolide) (PLGA) particles would 
be more appropriate adjuvant for anti-diphtheria vaccines 
than conventional alum due to their better efficiency, lon-
ger potency, and fewer side effects (10). The aim of this 
study was to assess the ability of cellobiose-coated PLGA 
particles carrying DT B-subunit to induce local and system-
ic humoral response after per os immunization of mice.
MATeriALS AnD MeThoDS
Antigen preparation
Fusion protein EGFP-SbВ consisting of the non-toxic re-
combinant subunit B of DT (SbB) and enhanced green 
fluorescent protein (EGFP) was used as a model antigen 
for immunization of mice. EGFP label was used for further 
monitoring of its antigen-adsorbing process by different 
fluorescent techniques.
Recombinant protein EGFP-SbВ was obtained as previously 
reported (11). Briefly, bacterial culture of Escherichia coli BL 
21 (DE3) Rosetta (Novagen, Reno, NV USA) transformed by 
genetic constructions based on plasmid vector pET-24a(+) 
(Novagen) was grown at 37°C under intensive stirring (250 
rpm) up to extinction A
600 – 0.5-0.7. Expression of the pro-
teins was triggered via incubation with 1 mM of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) up to 3 hours at 30°С 
under intensive stirring (250 rpm). Recombinant protein 
was purified on the Ni2+-NTA-agarose column and stored 
in PBS, рН = 7.2.
Preparation of PLGA particles
Two types of PLGA particles were prepared and character-
ized as previously described (12) with slight modifications:
(1) The PLGA particles of the first type (PLGA 1) were pre-
pared by solvent displacement method. Briefly, 3 mL of 0.5% 
w/v PLGA (lactide:glycolide – 65:35) (Sigma-Aldrich Co., St. 
Louis, MO, USA) in acetone were added drop-wise to 30 mL 
of pure distilled water under magnetic stirring. Acetone was 
evaporated overnight at room temperature. Afterwards par-
ticles suspension was filtered through 10 μm filter.
(2) The PLGA particles of the second type (PLGA 2) were 
prepared by double emulsification using solvent evapora-
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tion method. Briefly, 5 mL of 6% w/v PLGA in methylene 
chloride were homogenized with 1 mL of PBS at 14 000 
rpm for 3 min with MPW-309 homogenizer (Universal Lab-
oratory Aid, Warsaw, Poland). Afterwards, the water-in-oil 
emulsion was added to 150 mL of distilled water contain-
ing dioctyl sulfosuccinate surfactant (Sigma-Aldrich Co.) 
(0.5% w/w PLGA) and homogenized at 7500 rpm for 10 
min in an ice bath. Methylene chloride was evaporated 
overnight at room temperature, after which particles sus-
pension was filtered through 10 μm filter.
Loading of protein antigens on PLGA particles
PLGA 1 and PLGA 2 particles were collected by centrifu-
gation at 12 000 g for 3 min and resuspended in PBS con-
tained EGFP-SbВ (1% w/w PLGA). The emulsion was stirred 
overnight on magnetic stirrer at 4°С. Afterwards, the parti-
cles were collected by centrifugation for 3 min at 12 000 g. 
In order to increase the stability, the purified particles were 
coated in 129 mM cellobiose (Sigma-Aldrich Co.) in PBS for 
24 h at 4°C. The suspension of particles was centrifugated 
for 3 min at 12 000 g, the pellet was resuspended in 1 mL 
of PBS and stored at 4°С.
electrophoretic separation of proteins
10% SDS polyacrylamide gel electrophoresis was per-
formed in compliance with the methodology of Schagger 
and von Jagow (13).
Characterization of PLGA particles
Morphological examination of the particles was performed 
with a transmission electron microscope (TEM) Hitachi 
H-600 (Hitachi, Japan). The mean size of antigen-loaded 
PLGA particles was determined using a laser diffraction-
based particle size analyzer Zetasizer-3 (Malvern Instru-
ments Co, Malvern, UK). The results were processed using 
computer software service PCS-Size mode v. 1.61 (Malvern 
Instruments).
J774 cell line culture
The murine macrophage-like cell line J774 was obtained 
from the Cell Cultures Bank of Kavetsky Experimental Pa-
thology Oncology and Radiobiology Institute of NAS of 
Ukraine. J774 cell line was cultivated in RPMI-1640 medium 
containing L-glutamine with addition of 5% FCS (fetal calf 
serum), streptomycin (100 mg/L), penicillin (10 000 U), and 
amphotericin В (250 μg/L) at 37°С, 5% СО2 concentration.
Flow cytometry
J774 cells were detached from the flask by addition of 20 
mM ЕDTA in PBS. Optimal quantity of cells for staining was 
0.3-0.5 × 106 per probe. To investigate sorption efficiency of 
particles, J774 cells were stained by incubation with par-
ticles, which contained 3 μg of protein in 1 mL BSA-PBS-
NaN3 solution (1% BSA and 0.02% NaN3 in PBS) for 15 min 
at 4°С. To investigate phagocytic efficiency, cells were in-
cubated with particles that contained 3 μg of protein in 
1 mL BSA-PBS solution (1% BSA in PBS) for 60 min at 37°С. 
Thereafter, non-bound particles were washed up twice by 
BSA-PBS solution. Fluorescence intensity of cells was de-
termined by Coulter Epics XL flow cytometer (Beckman 
Coulter, Brea, CA. USA) via FL1 channel (515-535 nm).
Preparation of cell specimens for confocal microscopy
J744 cells were grown on microscope coverslips to semi-
confluent state and were washed by RPMI-1640, pH 7.3. 
Particles containing 2.5 μg of protein and cell nuclear dye 
Hoechst 33342 in 1 mL RPMI-1640 were incubated with 
cells for 15 min at 4°С and for 60 min at 37°С. Non-bound 
proteins were washed twice by RPMI-1640. After incuba-
tion, J774 cells were fixed by 4% solution of paraformal-
dehyde in 0.1 M phosphate buffer for 40 min at 4°С. Cov-
erslips with cells were mounted on a slide in mounting 
medium based on polyvinyl alcohol. Cell specimens were 
analyzed with confocal microscope Zeiss LSM 510 Meta 
(Carl Zeiss, Jena, Germany) with oil immersion objective 
Plan-Apochromat 63x/1.4 Oil DIC.
immunization of mice
Immunization was carried out on BALB/c female mice of 
the same age (6 weeks) and weight ( ~ 20 g) in strict ac-
cordance with the recommendations in NIH Guide for the 
Care and Use of Laboratory Animals. The protocol was ap-
proved by the Committee on the Ethics of Animal Experi-
ments of the Palladin Institute of Biochemistry of NAS of 
Ukraine (Protocol #2 from 19/09/2012).
Animals had free access to food and water during the im-
munization study. They were deprived of water 24 h prior 
to immunization. Mice were fed per os with 25 µL of solu-
ble PLGA particles functionalized with EGFP-SbВ and cel-
lobiose in PBS. Eight groups of mice (9 mice per group) 
were immunized orally with different doses of PLGA 1 
and PLGA 2 particles having immobilized antigen (2.5 
µg, 25 µg, 250 µg, and 2500 µg of antigen per 1 kg 
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of body weight) three times with intervals of two weeks 
on days 0, 14, and 28. 100 µL of blood samples were taken 
from the tail vein before immunization and one week after 
each immunization. Blood samples were centrifuged for 20 
min at 2800 rpm. The sera samples were stored at -20°C.
Determination of antigen-specific igG and igA in sera
IgG and IgA antibodies against SbB were determined by 
enzyme-linked immunosorbent assay (ELISA). Antigen (10 
µg/mL in PBS) was adsorbed on the bottom of 96-wells 
plates (Microlon ELISA-plates, High-Binding, Greiner Bio 
One, Frickenhausen, Germany) by overnight incubation at 
4°C. The plates were washed three times with 0.04% v/v 
Tween® 20 in PBS (PBST) and blocked with PBS-skim milk 
powder (1% w/v) for 1 h at 37°C, followed by washing with 
PBST. The serum samples were serially diluted with PBST, 
and 100 μL of each sample was added to each well. The 
plates were incubated for 60 min at 37°C and washed three 
times with PBST. Afterwards, 100 µL of peroxidase-conju-
gated anti-mouse IgG/IgA (Sigma) were added accord-
ing to the manufacturer’s instructions and incubation was 
repeated. The plates were washed three times with PBST. 
Then, 100 mL of tetramethyl benzidine solution was added 
to each well and after 15 min the reaction was stopped by 
addition of 2N H2SO4. The optical density (OD) was mea-
sured at 450 nm.
reSuLTS
Preparation and characterization of PLGA particles
In order to prepare suitable carriers for the delivery of an-
tigen to mice MALT we used two methods of PLGA par-
ticles synthesis, which resulted in the formation of parti-
cles with different size and structure PLGA 1 were prepared 
by solvent displacement method and PLGA 2 – by double 
emulsification with solvent evaporation method. TEM re-
sults showed that both types of particles had similar oval 
to round shape (Figure 1). The final particles mean size 
and polydispersity index (PDI) after the antigen-loading 
and cellobiose coating were measured using a Zetasizer. 
The PDI values for these particles ranged from 0.3 to 0.4, a 
higher value indicating a less homogeneous particle size 
distribution. Batches of PLGA-cellobiose-1 had a mean size 
of 870 nm and a PDI of 0.406, whereas batches of PLGA-
cellobiose-2 had a mean size of 1189 nm and a PDI of 0.3. 
More detailed analysis showed that both types of the par-
ticles had heterogeneous distribution of mean size. Thus, 
the batch of PLGA-cellobiose-1 particles was composed 
TAbLe 1. Main properties of synthesized poly (lactide-co-glycolide) (PLGA) particles
Properties PLGA 1 PLGA 2
Size before antigen loading and cellobiose coating, nm 8-35 10-100
Size after antigen loading and cellobiose coating (mean size±SD), nm 870 ± 14 1189 ± 39
Mean size distribution (number %), nm 178.6 (33) 707.1 (67) 495.2 (71) 1143 (29)
Average efficiency of antigen loading (μg/mg) 4.6 9.0
Polydispersity index after antigen loading and cellobiose coating 0.406 ± 0.059 0.300 ± 0.057
FiGure 1. TeM photomicrograph of poly (lactide-co-glycolide) (PLGA) particles samples prepared by methods 1 and 2.
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of two populations of particles with distinct mean sizes – 
178.6 nm (33%) and 707.1 nm (67%); whereas the batch 
of PLGA-cellobiose-2 was composed of particles with the 
mean sizes of 495.2 nm (79%) and 1143 nm (21%). Also, 
SDS PAGE showed that the amount of antigen entrapped 
in the PLGA-cellobiose-1 was 15% higher than in the PLGA-
cellobiose-2 particles (Table 1). Thus, we obtained particles 
with immobilized antigen, which considerably increased 
their size after functionalization with cellobiose.
interaction of PLGA-cellobiose particles with J744 cells
Mouse macrophage cell line J774 was incubated with PL-
GA-cellobiose particles of types 1 and 2 during 15 min at 
4°С to determine the sorption efficiency and during 60 min 
at 37°С to evaluate the ability of particles to induce phago-
cytosis by J774 cells. E coli cells expressing green fluores-
cent protein EGFP were used for comparison of phagocytic 
activity, since they are considered a standard of effective 
sorption and internalization due to immunotropic proper-
ties of lipopolysaccharides and other components of bac-
terial origin on their surface.
Cell fluorescence intensity was determined with Coulter 
Epics XL (Beckman Coulter) flow cytometer. J774 cells ef-
fectively adsorbed both types of PLGA-cellobiose parti-
cles and bacteria at 4°С and 37°С. Surprisingly, J774 cells 
interacted with particles better than with bacteria. Also, 
PLGA-cellobiose-1 particles adsorbed and internalized by 
macrophage cells on average 10% more effectively than 
PLGA-cellobiose-2. Thus, J774 cells showed a high up-
take efficiency of particles in the range: PLGA-cellobiose-2 
– 40%; PLGA-cellobiose-1 – 31%; E.coli – 21% (Figure 2). 
Consequently, we obtained particles highly attractive for 
immune cells. Moreover, different types of these particles 
differed in their ability to bind phagocytic cells.
J744 cells were fixed after incubation with the particles and 
were analyzed by Zeiss LSM 510 Meta (Carl Zeiss) confo-
cal microscope (Figure 3). J744 macrophage cells bound 
PLGA-cellobiose particles on their surface, and the interac-
tion between cells and particles was strong enough to pre-
vent washing them away with buffer solution during the 
procedure of microscopic slide preparation. The confocal 
images were in good agreement with the results obtained 
by flow cytometry.
PLGA-cellobiose particles interacted with J744 cells more 
effectively than E coli cells. Interaction of PLGA-cellobiose-1 
particles with J774 cells was weaker at 4°C than at 37°C. In 
fact, particles of type 1 were almost not bound by J744 cells 
after incubation at 4°C during 15 min compared to parti-
cles type 2, which remained bound by cells under these 
conditions. Moreover, we showed a more efficient uptake 
of PLGA-cellobiose-2 particles compared to PLGA-cellobi-
ose-1 by J744 macrophage cells. We believe that this effect 
appeared due to bigger average size of PLGA-cellobiose-2 
particles, which is closer to the natural size of bacteria cells. 
Based on this, it could be assumed that PLGA-cellobiose-2 
particles have better interaction with phagocytic cells in 
vivo and thus possess more intensive immunogenic prop-
erties than PLGA-cellobiose-1 particles.
immunization of mice and analysis of dose-dependent 
systemic immune responses
Both types of obtained PLGA-cellobiose particles interact-
ed with macrophage-like cells, as was shown by flow cy-
tometry and confocal microscopy, and did not show any 
dose-dependent cytotoxic effect in vitro (data not shown). 
By their size and shape these particles resembled bacterial 
cells. Therefore, we suppose that they should also interact 
similarly as bacteria with M-cells of Peyer’s patches at the 
small intestine or other possible phagocytic cells of mu-
rine MALT. Therefore, these antigen-delivery compositions 
could possess some defined immunogenic potential and 
are suitable for studies in vivo.
FiGure 2. histograms of phagocytosis efficiency for J774 cells, which were incubat-
ed with fluorescent poly (lactide-co-glycolide) (PLGA)-cellobiose particles, E coli, or 
without any fluorescently labeled agent (control) at 4°С (incubation time – 15 min) 
and 37°С (incubation time – 1h). The amount of positively stained, ie, phagocytic 
cells was calculated as a gate, which restricted cells with higher than unstained 
cells fluorescent intensity. Gate was determined with positive control cells, which 
were incubated with E coli.
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The aim of in vivo study was to determine the dynamics of 
systemic humoral immune response after mice oral vac-
cination with different doses of antigen-loaded particles. 
For this purpose PLGA-cellobiose particles 1 and 2 were 
administered per os at days 7, 21, 28 and 35 in doses of 
2.5, 25, 250, and 2500 μg of antigen per kilogram of mice 
body weight. Serum samples were collected at days 0, 14, 
28, and 42 after antigen-loaded PLGA particles administra-
tion (Figure 4).
IgG and IgA levels of antibodies in blood of animals were 
measured by ELISA. The number of animals with consider-
ably increased levels of immunoglobulins was determined 
for each group (Figure 5 and 6). All groups of animals im-
FiGure 4. The immunization chart: mice were immunized by two types of antigen- poly (lactide-co-glycolide) (PLGA) -cellobiose 
compositions: 8 groups (9 mice each) received different doses of PLGA-cellobiose particles type 1 and 2. blood collection is marked 
as red tubes and oral immunization is marked as yellow pipettes.
FiGure 3. Confocal images of J744 cells incubated with poly (lactide-co-glycolide) (PLGA)-cellobiose particles, E coli cells, or without 
any foreign fluorescently labeled agent (control) at 4°С (incubation time – 15 min) and 37°С (incubation time – 1h). Cell nuclei are 
stained in blue (hoechst 33342), cytoplasm is in red (autofluorescence at excitation wavelength of 560 nm) and antigen-loaded 
PLGA particles and E coli cells are stained in green (enhanced green fluorescent protein as label).
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munized with PLGA-cellobiose-1 and PLGA-cellobiose-2 
particles with the same doses of loaded antigen showed 
similar pattern of positive responses.
All mice immunized with 250 μg/kg of antigen associat-
ed with PLGA-cellobiose-2 particles had significantly ele-
vated levels of antibodies. The titers of antibodies after the 
first immunization in this group of animals were 1:800 and 
more in ELISA (data not shown). However, the level of an-
tibodies decreased after the second and third immuniza-
tions. The similar tendency was observed for the dose of 
250 μg/kg of antigen associated with PLGA-cellobiose-1 
particles.
The highest number of animals that had significantly posi-
tive levels of specific IgA antibodies was found in two 
groups: 25 μg/kg PLGA-cellobiose-1 after the first immu-
nization and 2.5 μg/kg PLGA-cellobiose-2 after the second 
immunization (Figure 6).
Thus, cellobiose-coated PLGA particles of both types were 
effective for oral immunization. However, after the second 
administration of PLGA-cellobiose particles a considerable 
part of immunized mice became tolerant. The number of 
tolerant animals was increasing after each subsequent ad-
ministration of particles. This process may represent the 
immune system tendency to develop an immune toler-
ance to repeatedly delivered antigens per os.
DiSCuSSion
Non-toxic DT mutants (cross-reacting materials) have al-
ready been applied in animal models to induce effective 
anti-diphtheria immune response (14). For example, in our 
previous study non-toxic recombinant subunit B of DT has 
been proposed as a safe and effective antigen with a good 
potential to elicit protective immune response in immu-
nized guinea pigs (15). However, the efficacy of the oral 
administration of free antigens is limited by their degrada-
tion in the gastrointestinal tract and poor absorption by M-
cells. On the other hand, pulmonary immunization route 
could be complicated by the development of the inflam-
mation observed in the lung tissues of the animals receiv-
ing antigen (16). Today, there is a number of biocompat-
ible particles with controlled volume that were developed 
for antigen delivery in per os immunization. Biodegradable 
polymers, like PLGA, are widely used for the design of these 
delivery vehicles (17). However, precise schemes of immu-
nization and antigen formulations are still to be developed 
for induction of anti-diphtheria immunity.
In this study, we examined humoral immune responses 
in mice immunized with DT B-subunit loaded PLGA-cello-
biose microparticles. Two types of antigen-loaded PLGA-
cellobiose particles were obtained by different methods 
of synthesis. The particles had different average size and 
polydispersity index. They also differed by their capabil-
ity of engulfment of protein antigens and antigen release 
during their presence in MALT. Therefore, we could expect 
different immunogenic properties from these two kinds of 
antigen-delivery systems.
Immune response to the antigen is usually induced by its 
interaction with antigen-presenting cells (APC) of the im-
mune system, macrophages, and dendritic cells (18).
The monocytic macrophage-like cell line J744 derived 
from murine reticulum cell sarcoma was used to 
FiGure 5. The number of animals with significantly positive levels of serum 
specific igG, which were immunized orally with different doses of antigen-
loaded to poly (lactide-co-glycolide) (PLGA)-cellobiose-1 (A) and PLGA-
cellobiose-2 (B). The serum was collected at days 0, 14, 28, and 42. The total 
number of animals per bar was 9.
RECOOP for Common Mechanisms of Diseases 92 Croat Med J. 2015;56:85-93
www.cmj.hr
study particles’ interaction with APC. It was found that sorp-
tion of E coli cells to J744 macrophages at 4°C for 15 min is 
almost the same as sorption of PLGA-cellobiose-2 particles 
and even better than that of PLGA-cellobiose-1. However, 
internalization of particles of both types was more effec-
tive than internalization of E coli cells (37°C, 60 min). Thus, 
effective interaction between obtained antigen-PLGA-cel-
lobiose compositions and APC was demonstrated in vitro.
Since synthesized particles could bind to the macrophage 
antigen-presenting cells in vitro, it could be assumed that 
similar effects would also be observed in vivo. Particularly, 
when particles are administered into the body by immu-
nization, they might interact with APCs of the immune 
system and stimulate the development of a specific im-
mune response to the antigen (19). Nevertheless, it is 
also necessary to take into account the ability of the 
gastrointestinal tract to induce immune tolerance (20). 
Therefore, we decided to investigate whether our com-
posites maintained their properties and caused immune 
response when administered orally to mice. Experimental 
animals were immunized with different types of particles 
at various doses, which allowed us to find out how the 
amount of antigen in the particles could influence the de-
velopment of immune response.
The increase in specific antibodies in blood of animals was 
observed for both types of particles at any doses exam-
ined. Higher level of IgG specific to recombinant subunit 
B was found when the dose of PLGA-cellobiose-2 particles 
was administered at 250 μg/kg. All mice in this group had 
a significant increase in specific IgG level in plasma. Since 
IgG are the main component of humoral immunity, syn-
thesized PLGA composites could be considered as the ef-
fective carrier for the antigen delivery and for induction of 
humoral immune response. The highest levels of specific 
IgA were found in the group of animals immunized with 
250 μg/kg PLGA-cellobiose-1 particles. Notably, the secre-
tory IgA are the main protective antibodies on mucosal 
surfaces. The rate of secretory IgA correlates positively with 
their level in blood. So, the increased levels of IgA can indi-
cate a possible increase in mucosal protection under oral 
administration.
However, in many cases, upon repeated administration 
of particles, the level of antigen-specific antibodies was 
reduced, pointing at the development of oral tolerance. 
Nevertheless, for the formulation of convenient oral vac-
cine this tendency is not significant as in this case only one 
administration of vaccine is required for the development 
of high immune response and further immunizations are 
not necessary.
In conclusion, two methods of antigen-PLGA-cellobiose 
composition were developed and appropriate particles 
were synthesized according to these methods. The inter-
action with monocyte-macrophagal antigen-presenting 
cells in vitro and their influence on IgG and IgA response in 
vivo were studied in a mouse model. We found that PLGA 
conjugated DT B-subunit could induce enhanced levels of 
antigen-specific IgG and IgA in the serum after first immu-
nization. The mechanisms of particle penetration into the 
immune cells and their interaction with immune system 
require further study.
Acknowledgments We thank our colleagues: Dr Olexander Chunihin for 
help in the experiment with dynamic light scattering, Dr Volodymyr Cher-
nyschov for TEM, Dr Serhiy Korahim for help with confocal microscopy, and 
FiGure 6. The number of animals with significantly positive levels of serum 
specific igA, which were immunized orally with different doses of antigen-
loaded poly (lactide-co-glycolide) (PLGA)-cellobiose-1 (A) and PLGA-
cellobiose-2 (B). The serum was collected at days 0, 14, 28, and 42. The total 
number of animals per bar was 9.
93Chudina et al: Cellobiose-coated PLGA particles with diphtheria toxoid for per os immunization
www.cmj.hr
Dr Olena Oliinyk and Ms. Natalia Korotkevych, for contributing to the ideas 
of our research work.
Funding This work was supported by the Grant of National Academy of Sci-
ences of Ukraine 0110U005961.
ethical approval received from the Animal Care and Use Committee of the 
Palladin Institute of Biochemistry (Protocol No. 2 approved on 19/09/2012).
Declaration of authorship TC, AL, DK, KM, and SK participated in designing 
the experiments. LA performed confocal microscope data collection and 
flow cytometry. KM was engaged in maintaining the eukaryotic cell lines. 
TC performed mice immunization, preparation of serum samples, and ELISA 
data collection. TC, AL, DK, KM, and SK wrote and prepared the manuscript. 
KD and SK were the heads of the research program.
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
references
1  hadfield TL, Mcevoy P, Polotsky Y, Tzinserling VA, Yakovlev AA. The 
pathology of diphtheria. J infect Dis. 2000;181 Suppl 1:S116-20. 
Medline:10657202 doi:10.1086/315551
2 rey M, Patey o, Vincent-ballereau F. Diphtheria s european come 
back. euro Surveill. 1996;1:14-6. Medline:12631744
3 Adler nr, Mahony A, Friedman nD. Diphtheria: forgotten, but 
not gone. intern Med J. 2013;43:206-10. Medline:23402486 
doi:10.1111/imj.12049
4 Collier rJ. understanding the mode of action of diphtheria toxin: 
a perspective on progress during the 20th century. Toxicon. 
2001;39:1793-803. Medline:11595641 doi:10.1016/S0041-
0101(01)00165-9
5 Corthésy b. role of secretory igA in infection and maintenance of 
homeostasis. Autoimmun rev. 2013;12:661-5. Medline:23201924 
doi:10.1016/j.autrev.2012.10.012
6 Mabbott nA, Donaldson DS, ohno h, Williams ir, Mahajan A. 
Microfold (M) cells: important immunosurveillance posts in 
the intestinal epithelium. Mucosal immunol. 2013;6:666-77. 
Medline:23695511 doi:10.1038/mi.2013.30
7 Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. enhancing oral 
vaccine potency by targeting intestinal M cells. PLoS Pathog. 
2010;6:e1001147. Medline:21085599 doi:10.1371/journal.
ppat.1001147
8 Shukla A, Singh b, Katare oP. Significant systemic and mucosal 
immune response induced on oral delivery of diphtheria 
toxoid using nano-bilosomes. br J Pharmacol. 2011;164:820-7. 
Medline:21506959 doi:10.1111/j.1476-5381.2011.01452.x
9 Mcneela eA, o’Connor D, Jabbal-Gill i, illum L, Davis SS, Pizza M, 
et al. A mucosal vaccine against diphtheria: formulation of cross 
reacting material (CrM(197)) of diphtheria toxin with chitosan 
enhances local and systemic antibody and Th2 responses following 
nasal delivery. Vaccine. 2000;19:1188-98. Medline:11137256 
doi:10.1016/S0264-410X(00)00309-1
10 Yuki Y, Kiyono h. Mucosal vaccines: novel advances in 
technology and delivery. expert rev Vaccines. 2009;8:1083-97. 
Medline:19627189 doi:10.1586/erv.09.61
11 Kaberniuk AA, Labyntsev Aiu, Kolybo DV, oliĭnyk oS, redchuk TA, 
Korotkevych nV, et al. Fluorescent derivatives of diphtheria toxin 
subunit b and their interaction with Vero cells. [in ukrainian]. ukr 
biokhim Zh. 2009;81:67-77. Medline:19877418
12 Davies G, editor. Vaccine adjuvants: methods and protocols. new 
York, nY: humana Press; 2010.
13 Schägger h, von Jagow G. Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins 
in the range from 1 to 100 kDa. Anal biochem. 1987;166:368-79. 
Medline:2449095 doi:10.1016/0003-2697(87)90587-2
14 romaniuk Si, Kolibo Db, Komisarenko SV. Perspectives of 
application of recombinant diphtheria toxin derivatives. [in 
russian]. bioorg Khim. 2012;38:639-52. Medline:23547467
15 Kaberniuk AA, oliĭnyk oS, Kolybo DV, Komisarenko SV. Toxin-
neutralizing properties of antibodies to diphtheria toxin 
recombinant subunits A and b and a new method of their 
estimation [in ukrainian]. ukr biokhim Zh. 2009;81:92-101. 
Medline:19877434
16 Muttil P, Pulliam b, Garcia-Contreras L, Fallon JK, Wang C, hickey 
AJ, et al. Pulmonary immunization of guinea pigs with diphtheria 
CrM-197 antigen as nanoparticle aggregate dry powders enhance 
local and systemic immune responses. AAPS J. 2010;12:699-707. 
Medline:20878294 doi:10.1208/s12248-010-9229-6
17 Pavot V, berthet M, rességuier J, Legaz S, handké n, Gilbert SC, 
et al. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles 
as versatile carrier platforms for vaccine delivery. nanomedicine 
(Lond). 2014;9:2703-18. Medline:25529572 doi:10.2217/
nnm.14.156
18 Mantegazza Ar, Magalhaes JG, Amigorena S, Marks MS. 
Presentation of phagocytosed antigens by MhC class i and ii. 
Traffic. 2013;14:135-52. Medline:23127154 doi:10.1111/tra.12026
19 Chadwick S, Kriegel C, Amiji M. nanotechnology solutions for 
mucosal immunization. Adv Drug Deliv rev. 2010;62:394-407. 
Medline:19931581 doi:10.1016/j.addr.2009.11.012
20 ohtsuka Y. Food intolerance and mucosal inflammation. Pediatr 
int. 2015;57:22-9. Medline:25442377 doi:10.1111/ped.12546
